Clinuvel Pharmaceuticals Ltd
ASX:CUV

Watchlist Manager
Clinuvel Pharmaceuticals Ltd Logo
Clinuvel Pharmaceuticals Ltd
ASX:CUV
Watchlist
Price: 13.05 AUD 2.76%
Market Cap: 655.1m AUD

Clinuvel Pharmaceuticals Ltd
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Clinuvel Pharmaceuticals Ltd
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Clinuvel Pharmaceuticals Ltd
ASX:CUV
Operating Income
AU$45.7m
CAGR 3-Years
9%
CAGR 5-Years
27%
CAGR 10-Years
N/A
Opthea Ltd
ASX:OPT
Operating Income
-$155.9m
CAGR 3-Years
-17%
CAGR 5-Years
-56%
CAGR 10-Years
-34%
Mesoblast Ltd
ASX:MSB
Operating Income
-$82.3m
CAGR 3-Years
-4%
CAGR 5-Years
-2%
CAGR 10-Years
1%
CSL Ltd
ASX:CSL
Operating Income
$4.1B
CAGR 3-Years
12%
CAGR 5-Years
9%
CAGR 10-Years
9%
Telix Pharmaceuticals Ltd
ASX:TLX
Operating Income
AU$51.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
PYC Therapeutics Ltd
ASX:PYC
Operating Income
-AU$49.7m
CAGR 3-Years
-52%
CAGR 5-Years
-48%
CAGR 10-Years
-26%
No Stocks Found

Clinuvel Pharmaceuticals Ltd
Glance View

Market Cap
654.1m AUD
Industry
Biotechnology

Clinuvel Pharmaceuticals Ltd. operates as a biopharmaceutical company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-02-13. The firm is focused on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders, as well as healthcare solutions for the general population. The Company’s principal activity consists of commercializing and distribution in Europe and the United States of its drug candidate SCENESSE for the treatment of a rare, genetic metabolic disorder erythropoietic protoporphyria (EPP). The company is also focused on developing and commercializing SCENESSE as a combination with narrowband ultraviolet B (NB-UVB) phototherapy and topical pharmaceutical formulations of melanocortin analogues for the treatment of the skin depigmentation disorder vitiligo. Its research and development of PRENUMBRA, a new liquid formulation of afamelanotide for the treatment of acute disorders and vascular anomalies.

CUV Intrinsic Value
17.45 AUD
Undervaluation 25%
Intrinsic Value
Price

See Also

What is Clinuvel Pharmaceuticals Ltd's Operating Income?
Operating Income
45.7m AUD

Based on the financial report for Jun 30, 2025, Clinuvel Pharmaceuticals Ltd's Operating Income amounts to 45.7m AUD.

What is Clinuvel Pharmaceuticals Ltd's Operating Income growth rate?
Operating Income CAGR 5Y
27%

Over the last year, the Operating Income growth was -17%. The average annual Operating Income growth rates for Clinuvel Pharmaceuticals Ltd have been 9% over the past three years , 27% over the past five years .

Back to Top